Enhanced immunogenicity of a Clostridioides difficile TcdB vaccine adjuvanted with a synthetic dual-TLR ligand adjuvant
We report a comprehensive evaluation of the toxin B (TcdB) vaccine adjuvanted with a dual Toll-like receptor ligand liposome adjuvant for Clostridioides difficile infection (CDI). The vaccine completely protected mice from a lethal infection. Compared to alum adjuvanted TcdB, it generated functionally superior systemic antibodies and supported strong memory B cell and gut IgA responses. This pharmaceutically acceptable adjuvant platform holds promise for developing a next-generation CDI vaccine.
Authors
- Farha Naz (ORCID: https://orcid.org/0000-0003-0647-4613)
- Christopher B. Fox (ORCID: https://orcid.org/0000-0002-4644-2619)
- William A. Petri (ORCID: https://orcid.org/0000-0002-7268-1218)
- G. Brett Moreau (ORCID: https://orcid.org/0000-0001-6032-4320)
- Joel Herbein
- Brandon Thompson (ORCID: https://orcid.org/0000-0003-2148-4086)
- Mayuresh M. Abhyankar
- Feifan Xu
- Nicholas Hagspiel
Institutions
- University of Virginia Health System (US)
- TechLab (United States) (US)
- Access to Wholistic and Productive Living Institute (US)
- University of Virginia (US)
Publication Details
- Journal
- npj Vaccines
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1038/s41541-025-01075-3
- Citations
- 4
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- National Institutes of Health